/CNW/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Medicines Agency's (EMA) CHMP has recommended approval of...
A mixed trial could hurt a kidney drug's chances of full approval.
These stocks come with significant risks. But they could generate huge returns over time.
/PRNewswire/ -- Attention Travere Therapeutics, Inc. ("Travere") (NASDAQ: TVTX) shareholders: The Law Offices of Vincent Wong announce that an investigation...
/PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Travere...
/PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere") (NASDAQ: TVTX) concerning...
/PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Travere Therapeutics, Inc. ("Travere") (NASDAQ: TVTX) violated federal...
/PRNewswire/ -- Attention Travere Therapeutics, Inc. ("Travere") (NASDAQ: TVTX) shareholders: The Law Offices of Vincent Wong announce that an investigation...
/PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere") (NASDAQ: TVTX) concerning...
Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.